Combination of bleomycin, etoposide and cisplatin (BEP) versus etoposide and cisplatin (EP) in patients with good risk nonseminomatous germ cell tumors (NSGCT)

被引：0
作者：
Tryakin, A. [1 ]
Fedyanin, M. [1 ]
Bulanov, A. [1 ]
Titov, D. [1 ]
Mitin, A. [2 ]
Sergeev, J. [3 ]
Figurin, K. [2 ]
Fainstein, I. [3 ]
Matveev, V. [2 ]
Zakharova, T. [4 ]
Kostjakova, L. [5 ]
Garin, A. [1 ]
Tjulandin, S. [1 ]
机构：
[1] NN Blokhin Russian Canc Res Ctr, Clin Pharmacol & Chemotherapy, Moscow, Russia
[2] NN Blokhin Russian Canc Res Ctr, Urol, Moscow, Russia
[3] NN Blokhin Russian Canc Res Ctr, Radiosurg, Moscow, Russia
[4] NN Blokhin Russian Canc Res Ctr, Pathomorphol, Moscow, Russia
[5] NN Blokhin Russian Canc Res Ctr, Radiol, Moscow, Russia
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31428-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2610
引用
收藏
页码：S515 / S515
页数：1
相关论文
共 50 条
  • [21] The safety and efficacy of bleomycin, etoposide and cisplatin (BEP) chemotherapy in patients with malignant ovarian germ cell tumor
    Lee, G.
    Park, J. Y.
    Kim, D. Y.
    Suh, D. S.
    Kim, J. H.
    Kim, Y. M.
    Kim, Y. T.
    Nam, J. H.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S96 - S96
  • [22] Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial
    Culine, S
    Theodore, C
    TerrierLacombe, MJ
    Droz, JP
    JOURNAL OF UROLOGY, 1997, 157 (03) : 855 - 858
  • [23] CISPLATIN, VINBLASTINE, AND BLEOMYCIN VERSUS VINBLASTINE, CISPLATIN, AND ETOPOSIDE IN THE TREATMENT OF ADVANCED GERM-CELL TUMORS OF THE TESTIS - REPLY
    WOZNIAK, AJ
    CUMMINGS, G
    JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (06) : 1093 - 1094
  • [24] CISPLATIN-ETOPOSIDE AND CARBOPLATIN-ETOPOSIDE INDUCTION CHEMOTHERAPY FOR GOOD-RISK PATIENTS WITH GERM-CELL TUMORS
    TJULANDIN, SA
    GARIN, AM
    MESCHERYAKOV, AA
    PEREVODCHIKOVA, NI
    GORBUNOVA, VA
    SOKOLOV, AV
    LJUBIMOVA, NV
    MIRONOVA, GT
    MOLCHANOV, GV
    OZOLS, RF
    HAMILTON, JM
    ANNALS OF ONCOLOGY, 1993, 4 (08) : 663 - 667
  • [25] TREATMENT OF MALIGNANT GERM-CELL TUMORS OF THE OVARY WITH BLEOMYCIN, ETOPOSIDE, AND CISPLATIN
    GERSHENSON, DM
    MORRIS, M
    CANGIR, A
    KAVANAGH, JJ
    STRINGER, CA
    EDWARDS, CL
    SILVA, EG
    WHARTON, JT
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (04) : 715 - 720
  • [26] INCREASED RISK OF MYELODYSPLASIA AND LEUKEMIA AFTER ETOPOSIDE, CISPLATIN, AND BLEOMYCIN FOR GERM-CELL TUMORS
    PEDERSENBJERGAARD, J
    DAUGAARD, G
    HANSEN, SW
    PHILIP, P
    LARSEN, SO
    RORTH, M
    LANCET, 1991, 338 (8763) : 359 - 363
  • [27] Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors
    Funt, Samuel A.
    McHugh, Deaglan J.
    Tsai, Stephanie
    Knezevic, Andrea
    O'Donnell, Devon
    Patil, Sujata
    Silber, Deborah
    Bromberg, Maria
    Carousso, Maryann
    Reuter, Victor E.
    Carver, Brett S.
    Sheinfeld, Joel
    Motzer, Robert J.
    Bajorin, Dean F.
    Bosl, George J.
    Feldman, Darren R.
    ONCOLOGIST, 2021, 26 (06) : 483 - 491
  • [28] TREATMENT OF FAVORABLE-PROGNOSIS NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS WITH ETOPOSIDE, CISPLATIN, AND REDUCED DOSE OF BLEOMYCIN
    BRADA, M
    HORWICH, A
    PECKHAM, MJ
    CANCER TREATMENT REPORTS, 1987, 71 (06): : 655 - 656
  • [29] Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors
    Nakagawa, Ryunosuke
    Iwamoto, Hiroaki
    Makino, Tomoyuki
    Kadomoto, Suguru
    Yaegashi, Hiroshi
    Iijima, Masashi
    Kawaguchi, Shohei
    Nohara, Takahiro
    Shigehara, Kazuyoshi
    Izumi, Kouji
    Kadono, Yoshifumi
    Mizokami, Atsushi
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [30] Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients
    Gutierrez-Delgado, F
    Titov, DA
    Tjulandin, SA
    Garin, AM
    NEOPLASMA, 1999, 46 (03) : 190 - 195
12345